Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) jumped 3.3% in the morning session after the company ...

In 2025, sales are anticipated to grow by a high single-digit percentage at CER (previously mid-to-high single-digit). Sanofi confirms the expectation of a strong business EPS rebound with growth at a ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is one of the Best Extremely Profitable Stocks to Buy Right Now . On July 22, ...

Regeneron Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a double-digit profit ...

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Astegolimab, an anti-ST2 monoclonal antibody designed to block signaling of IL-33 under development by Roche's (OTCQX:RHHBY) Genentech unit, failed to meet its primary endpoint in a phase 3 trial for ...

On May 30, 2025, Sanofi issued a press release announced mixed data from a Phase 3 program for itepekimab, an antibody therapy targeting the lung disorder chronic obstructive pulmonary disease.

Merck has agreed to a $10-billion buyout of Verona Pharma and its first-in-class, potential COPD blockbuster Ohtuvayre.

RBC Capital maintained a Sector Perform rating on Regeneron, with a price target of $662, following challenges in the itepekimab program. A survey conducted by RBC Capital indicated investor interest ...

Bull Case How might positive itepekimab data impact Regeneron’s valuation? Positive data from the itepekimab COPD trials could significantly boost Regeneron’s prospects and stock valuation.